U.S. Food and Drug Administration Approves Mogamulizumab-kpkc (Poteligeo) for Two Most Common Types of Cutaneous T-Cell Lymphoma
New York, NY (August 8, 2018) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (August 8, 2018) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (June 13, 2018) –The U.S. Food and Drug Administration (FDA) granted accelerated…
New York, NY (June 8, 2018) – The U.S. Food and Drug Administration (FDA) announced…
New York, NY (May 1, 2018) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (March 20, 2018) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (October 19, 2017) – The U.S. Food and Drug Administration (FDA) announced…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (November 9, 2017) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it…
New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced…